INS and type 2 diabetes mellitus: Imeglimin is a tetrahydrotriazine that was recently approved to treat type 2 diabetes in Japan (2021) and India (2022) and which has been shown to improve glucose-induced insulin secretion, especially first phase, in clinical trials [14].